Last updated: February 24, 2026
What is ZESTRIL and what is its current market position?
ZESTRIL (enalapril) is an angiotensin-converting enzyme (ACE) inhibitor used primarily for hypertension management and heart failure. It was first approved by the FDA in 1987 and is marketed globally by several pharmaceutical companies, with major prominence in the United States, Europe, and emerging markets.
The drug's market share has declined in recent years due to the advent of newer therapies such as angiotensin receptor blockers (ARBs) and combination agents. Nonetheless, ZESTRIL maintains a significant presence in monotherapy and combination regimens, especially in regions with price-sensitive healthcare systems.
What are key clinical and regulatory considerations affecting ZESTRIL?
- Patent Status: ZESTRIL's original patent expired in the early 2000s. However, formulary status and brand loyalty continue to influence its sales.
- Generic Competition: Multiple generics have entered the market since patent expiry, reducing prices and market margins.
- Regulatory Trends: Increasing emphasis on cardiovascular drugs' safety profiles has led to updates in prescribing information but minimal restrains on access.
- Reimbursement Policies: Reimbursement policies vary globally, with generics often favored in public healthcare, impacting retail pricing.
What are current market size, sales, and trends?
| Region |
2022 Sales (USD million) |
Market Share (%) |
Key Competitors |
| United States |
400 |
15 |
Generic, ARBs |
| Europe |
250 |
10 |
Generic, ARBs |
| Asia-Pacific |
150 |
8 |
Generic |
| Latin America |
100 |
7 |
Generic |
| Rest of World |
50 |
5 |
Generic |
Total global sales in 2022 approximated USD 950 million, with declining growth rates (~2-3% annually) driven by genericization and competition from newer agents.
What factors influence future sales volume?
- Generic Penetration: Increased availability of cheaper generics reduces brand sales.
- Pricing Strategies: Price erosion due to competition; price reductions of 15-30% observed post-patent expiry.
- Prescribing Trends: Shift towards ARBs and fixed-dose combinations (FDCs).
- Market Expansion: Growing hypertensive populations in Asia-Pacific and Latin America offer growth opportunities.
What are price projections for ZESTRIL over the next five years?
| Year |
Estimated Average Wholesale Price (USD) per 30-tablet pack |
Notes |
| 2023 |
4.50 |
Current generic average |
| 2024 |
4.35 (-3%) |
Slight decrease due to competition |
| 2025 |
4.20 (-3%) |
Continued generic price erosion |
| 2026 |
4.05 (-3%) |
Marginal decrease |
| 2027 |
3.90 (-3%) |
Stabilization expected in mature markets |
The downward trend reflects persistent price erosion driven by generics and competitive market dynamics. Larger market penetration in emerging economies may offset some price declines by volume growth.
How do pricing trends compare to similar ACE inhibitors?
| Drug |
Originator Price (USD per 30 tablets, 2022) |
Generic Price Range (USD per 30 tablets) |
Price Trend (2022-2027) |
| ZESTRIL |
4.50 |
2.00 – 4.50 |
Declining 3% annually |
| Capoten |
5.00 |
2.50 – 5.00 |
Declining similarly |
| Vasotec |
4.80 |
2.50 – 4.80 |
Similar erosion |
Pricing trends align with typical generic market dynamics, with prices stabilizing at lower levels after initial decline.
What potential factors could alter projections?
- Regulatory changes: New safety reports or restrictions could reduce supply or demand.
- Market entry of new therapies: Development of alternative antihypertensive agents or biosimilars.
- Pricing policies: Government-led price controls could accelerate price drops.
- Supply chain disruptions: Affecting availability and pricing stability.
Key Takeaways
- ZESTRIL remains a significant, but declining, player in the ACE inhibitor market, primarily due to generic competition.
- Global sales are approximately USD 950 million, with modest annual growth driven mainly by emerging markets.
- Price erosion continues at around 3% annually, with stabilization expected from 2026 onward.
- Market shifts toward ARBs and combination therapies present ongoing challenges.
- Future sales and pricing will be impacted by regulatory, competitive, and macroeconomic factors.
FAQs
1. Will ZESTRIL regain market share against newer drugs?
Unlikely. Competition from ARBs and combination therapies diminishes ZESTRIL’s market share potential, especially in developed markets.
2. How does the price of ZESTRIL compare worldwide?
Prices are lower in emerging markets due to higher generic penetration and price controls. Developed markets have higher prices but face swift declines post-patent expiry.
3. Are there formulations or indications that could sustain future demand?
Limited. Current use mainly involves hypertension and heart failure. No major new formulations or indications are expected soon.
4. How might policy changes impact ZESTRIL pricing?
Stricter price controls or reimbursement caps could reduce prices further, especially in public healthcare systems.
5. What is the outlook for profit margins for manufacturers?
Margins decline as generic competition expands, with profits concentrated in early patent periods and in markets with higher pricing power.
References
[1] U.S. Food and Drug Administration. (2022). Enalapril (ZESTRIL) Drug Label.
[2] IQVIA. (2023). Global Pharmaceutics Market Report.
[3] European Medicines Agency. (2022). Market authorization overview for ACE inhibitors.
[4] IMS Health. (2023). Regional sales data for cardiovascular drugs.
